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Abstract 
Various novel non-estrogenic steroidal D-ring substituted analogs were synthesized and evaluated for their breast cancer 
activity against human breast cancer cell lines. The good cytotoxic results obtained against the breast cancer cell lines 
throws new insights into the field as the analogs are non 17β –Hydroxy estrogenic derivatives which are considered to be 
pivotal for the potent estrogenic activity. The synthesized steroidal analogs provide a very good platform for mechanistic 
studies of the interaction between non-esterogenic steroids and estrogen receptors. 
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Introduction 
Cancer, a fatal and devastating disease, needs no introduction. It will be hard to find a person who has not been 
traumatized by cancer amongst his family and friends. Amongst the women, breast cancer is one of the most common 
cancers. It is now well established that variour factors lead to the over-expression of estrogen receptors in breast tumour 
cells and, hence, estrogenicity is enhanced by many folds leading to excessive proliferation [1]. As steroids can regulate a 
variety of biological processes, they have the potential to be developed as drugs for the treatment of a large number of 
diseases including cancer [2]. Amongst the anticancer steroids, estrogens hold a potential for breast cancer treatment 
because of their antagonistic interaction with the Ligand binding domain (LBD) of the estrogen receptors ER-α and ER-β. 
The ligand receptor complex regulates the transcription of certain genes by binding to response elements in the promoter 
regions of the genes. The receptor protein activates the transcription machinery by a complex mechanism through the 
activating functions AF-1 and AF-2 in the estrogen receptor [1]. Broadly there are three types of ligands which bind to LBD 
but show different pharmacological activities. The three are full agonists such as estradiol, selective estrogen receptor 
modulators (SERMs) such as raloxifen and the full antagonists such as ICI 182, 780. It is however the last class of ligands 
i,e the full antagonists which are especially useful for the treatment of breast cancer [3]. The mechanistic studies related to 
differential ligand receptor interactions of agonists, SERMs and antagonists have been carried out through X-ray 
crystallography [4, 5]. 
Known estrogenic compounds contain a hydroxyl group or a hydroxy derivative at the 17-position, particularly 17β –
Hydroxy. This is considered to be essential to obtain high binding affinity. The non 17β –Hydroxy analogs have been 
shown to have low binding affinity or low estrogenic agonistic potency. However various recent reports have concluded 
that even some non-estrogenic compounds with different D-ring substitution pattern than that mentioned above can have 
higher binding affinity for the estrogen receptor and can thus eventually be used as antagonists against breast cancers [6]. 
Thus to check the activity of non estrogenic, non 17β –Hydroxy analogs , we, in continuation of our programme on the 
synthesis of D-ring substituted steroidal ananlogs for various pharmacological concerns [7], screened series of various 
novel D-ring substituted analogs for their breast cancer activity against MCF-7 breast cancer cell lines. The objective of 
the present work is thus to look for non-estrogenic non 17β –Hydroxy analogs which can be used for the treatment of 
breast cancers either through their binding affinity with the ER’s or through some other mechanism. 
2. Experimental: 
2.1. General methods 
 Melting points were recorded on Buchi Melting point apparatus D-545; IR spectra (KBr discs) were recorded on Bruker 
Vector 22 instrument. NMR spectra were recorded on Bruker DPX200 instrument in CDCl3 with TMS as internal standard 
for protons and solvent signals as internal standard for carbon spectra. Chemical shift values are mentioned in δ (ppm) 
and coupling constants are given in Hz. Mass spectra were recorded on EIMS (Shimadzu) and ESI-esquire 3000 Bruker 
Daltonics instrument. The progress of all reactions was monitored by TLC on 2x5cm pre-coated silica gel 60 F254 plates 
of thickness of 0.25mm (Merck). The chromatograms were visualized under UV 254-366 nm and iodine. 
2.2.1. Chemical synthesis 
(a) General procedure for the synthesis of chalconyl derivatives: To a solution of pregnenolone 1 (0.316g, 1mmol, 
1eq.) in ethanol (10ml) was added a conc. aq. solution of KOH (2 eq.). Then aldehyde 2 (1.2eq.) was charged into the 
reaction mixture to get the corresponding benzylidine derivative 3 (Scheme 1). After completion as revealed by thin layer 
chromatography (TLC) in an average span of around 1 hr, the reaction mixture was precipitated using water because of 
the limited solubility. The precipitate was filtered, dried and monitored through TLC for the purity. Thin layer 
chromatography revealed just a single spot which proved the presence of a single product. For further purification, the 
product was recrystallized from EtOAc:Hexane to give product as  solid white powder. It is to be mentioned that when non-
aromatic aldehydes were used, the product was formed in a very minor quantity and that too not stable enough at ambient 
conditions. Thus the study was restricted to the use of aromatic aldehydes only.  
(b) General procedure for the synthesis of pyrazoline derivatives: The benzylidine derivative 3 (1.0 g, 2.4 mmol) was 
refluxed in ethanol in the presence of hydrazine hydrate (0.24g, 4.8 mmol) so as to yield the desired pyrazolines. However 
the products thus obtained were very unstable and they decomposed even at ambient temperature conditions probably 
because of the inherent instability associated with pyrazolines. The solvent thus used was replaced by acetic acid so as to 
ensure the formation of N-acetyl pyrazoline 4 (0.99 g, 2.2 mmol, 90%) which was highly stable. The product was 
precipitated by charging the reaction mass into excessive amounts of ice-cold water (Scheme 2). After filtration under 
suction, the product was obtained in high yields as colorless powder which was later dried in vaccuo. The same procedure 
was followed for the synthesis of all other analogs.  
(c) General procedure for the synthesis of 1, 2, 3-triazolyl Pregnanes:To a solution of 21-Bromo pregnenolone 5 
(1eq.) in a mixture of tert. butanol and water was charged sodium azide (1.2 eq.) and the reaction was stirred for 30 min. 
Appropriate terminal alkyne 6 (1 eq.) was charged into the reaction mixture  along with copper sulphate (1.2 eq.) and 
stirring was continued for further 10 min. so as to allow complexation to occur. Sodium ascorbate (5 eq.) was added to the 
above mixture and the whole reaction mass allowed to stir at ambient conditions for 8-10 hrs. After the usual workup, the 
product was precipitated using hexane: ethylacetate mixture. Solid white triazolyl pregnanes 7 (Scheme 3) obtained were 
characterised using various spectral techniques.  
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The spectral data of representative compounds of each series are given below. For the detailed spectra of all compounds, 
our previous publications may be consulted [6]. 
(1) (2E)-1-((10R,13S)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3(b)-hydroxy-10,13-dimethyl-1H-
cyclopenta[a]phenanthren-17(b)-yl)-3-phenylprop-2-en-1-one (3a): White powder (86%). M.p: 128–131 
°
C; IR 
(KBr, cm-
1
): 3425, 2938, 1804, 1637, 1403, 1041, 689; 
1
H NMR (CDCl3, 200 MHz):   0.63 (s, 3H), 1.00 (s, 3H), 
1.61–1.90 (m, 6H), 2.20–2.38 (m, 3H), 2.82 (t, J = 8.80, 1H); 3.51 (m, 1H); 6.78 (s, J = 16.00, 1H), 7.39 (m, 3H), 
7.55 (m, 3H); 
13
C NMR (CDCl3, 125 MHz):  13.33, 19.26, 21.07, 22.67, 24.62, 31.13, 31.78, 31.99, 37.22, 41.81, 
45.11, 48.61, 48.78, 48.95, 49.12, 49.29, 50.04, 57.14, 61.97, 71.22, 121.24, 126.69, 128.29, 128.90, 130.41, 
134.62, 140.85, 141.96, 201.32; ESI-MS: 405 (M+H); Anal. Calcd. for C28H36O2: C, 83.12; H, 8.97; Found C, 
83.37; H, 8.83. 
(2) 1-(4,5-dihydro-3-((10R,13S)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3-hydroxy-10,13-dimethyl-
1H-cyclopenta[a]phenanthren-17-yl)-5-phenylpyrazol-1-yl) ethanone (4a): Colourless solid powder. Yield 
76%. M.p: 123-125 
°
C. [α]D
25
 – 16.9 (c 0.20, CHCl3). IR (KBr, cm-
1
): 3384, 2926, 1717, 1646, 1404, 1042, 699. 
1
H 
NMR (CDCl3, 200 MHz):  0.63 (s, 3  H), 1.06 (s, 3H), 1.82-1.90 (m, 6H), 2.17 (s, 3H), 2.65 (t, 1H, J =8.8), 2.79 
(m, 2H), 3.26 (m, 1H), 3.49 (m, 1H), 5.33 (s, 1H), 5.44 (m, 1H), 7.15 (d,  2H, J =6.5), 7.22-7.32 (m, 3H). 
13
C NMR 
(CDCl3, 125 MHz):  14.85, 20.85, 22.40, 23.32, 25.83, 31.13, 33.04, 33.48, 37.99, 38.72, 39.94, 43.68, 45.30, 
47.69, 51.53, 53.18, 57.94, 60.56, 73.11, 122.80, 126.78, 128.84, 130.28, 142.29, 160.63, 164.62. ESI-MS: 483 
(M
+
 + Na). Anal. Calcd. For C30H40N2O2: C, 78.22;  H, 8.75; N, 6.08; Found  C, 78.47; H, 8.83; N, 6.21.   
(3) 2-[4-(4-acetyl-phenoxy)-[1,2,3]triazol-1-yl]-1-(3-hydroxy-10-13-dimethyl-2,3,4,7,8,9, 10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-ethanone (7e): M.p: 107
o
C; [α]D 
25
 : (+)70; IR (KBr, cm
-
1
): 772, 1092, 1283, 1312, 1465, 1590, 1682, 2745, 2863, 2954, 3388; 
1
H NMR:  0.57 and 0.97 (2s, 6H), 3.35 
(m, 2H), 5.19 (s, 1H), 5.31 (s, 2H), 7.04 (d, 2H, J=9.80), 7.73 (s, 1H),7.95 (d, 2H, J=9.80);
 13
C NMR (500 MHz, 
CDCl3):  13.28, 19.44, 21.13, 22.87, 24.53, 31.81, 36.56, 37.30, 38.87, 42.23, 44.09, 50.01, 52.98, 56.36, 63.77, 
71.73, 118.51,120.12, 122.638, 124.81, 128.97, 130.65, 134.30, 135.34, 136.97, 137.14 140.81, 148.84 and 
209.99; ESI-MS: 554 (M
+ 
+ Na); Anal. Calc. for C32H41N3O4: C, 72.29; H, 7.77; N, 7.90. Found: C, 72.34; H, 7.74; 
N, 7.93. 
2.2.2. Biology: The human cancer cell lines against which the different series of steroidal analogs were screened were 
MCF-7 and T-47D (both Breast cancer cell lines) which were obtained from National cancer institute (NCI), biological 
testing branch, Federick Reserch and Development centre, USA. Cellular viability in the presence and absence of 
experimental agents was determined using the standard Sulforhodamine B assay. Briefly, cells in their log phase of growth 
were harvested, counted and seeded (10
4
 cells/well in 100 µL medium) in 96-well microtitre plates. After 24 h of incubation 
at 37° and 5% CO2 to allow cell attachment, cultures were treated with varying concentrations (0.1–100 µM) of test 
samples made with 1:10 serial dilutions. Four replicate wells were set up for each experimental condition. Test samples 
were left in contact with the cells for 48 h under same conditions. Thereafter, cells were fixed with 50% chilled 
trichloroacetic acid (TCA) and kept at 4
o
C for 1h, washed and air dried. Cells were stained with Sulforhodamine B dye. 
The adsorbed dye was dissolved in Tris-Buffer and plates were gently shaken for 10 min on a mechanical shaker. The 
optical density (OD) was recorded on ELISA reader at 540 nm. The cell growth was calculated by subtracting mean OD 
value of respective blank from the mean OD value of experimental set. Percent growth in presence of test material was 
calculated considering the growth in absence of any test material as 100% and in turn percent growth inhibition in 
presence of test material was calculated. Finally the IC50 values (Table IV) were calculated using Microsoft Office Excel. 
The different steroidal derivatives (test material) were dissolved in a mixture of DMSO:Water (1:1) and then introduced into 
the medium containing the cancer cell lines.  
2.3. Results and discussion: 
2.3.1. Introduction of biologically potent substitutions in the core structures of physiologically important molecules has 
since long been a fascinating subject of scientific investigation. This is especially true with respect to the rational 
modification of steroids. Though the importance of different steroidal D-ring heterocycles is now well validated, only few 
efforts have been reported for their efficient synthesis. This specially refers to the chalcone, pyrazoline and triazolyl based 
heterocycles at the D-ring of steroid. We have since long been in the area of designing various steroids based analogs 
with special focus towards their anticancer activities [7]. In continuation of the same program, we herein want to report the 
activity of various such analogs exclusively towards the breast cancer cell lines. The encouraging results have made it 
mandatory to go for the mechanistic studies which are currently in progress. The preparation of the various analogs has 
already been reported from time to time [7] with some different concerns as objectives. Here a special focus has been 
made towards the screening of these various non estrogenic analogs for their breast cancer activities.  
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Scheme 1: Synthesis of D-ring substituted steroidal chalcones. 
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Table 1: Nature of group "R" in the compounds 3a-3j
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Scheme 2: Synthesis of D-ring substituted steroidal pyrazolines. 
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O
Entry Nature of R Entry Nature of R
4a
4b
4c
4d
4e
4f
4g
4h
4i
4j
Table II: Nature of group "R" in the compounds 4a-4j
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Scheme 3: Synthesis of D-ring substituted steroidal triazoles. 
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7d
7e
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7i
Table III: Nature of benzene ring with group "R" in the compounds 7a-7i
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2.3.2: Biology. The following table gives the cancer cell inhibitory data obtained after treating breast cancer cell lines 
with test doses of the different steroidal derivatives and the values are reported in terms of IC50. 
 
Table IV. IC50 values (μM) of various non-estrogenic steroidal congeners against human breast cancer 
cell lines. 
 
                          ND = not determined;  
                          Cell lines: MCF-7 (Breast) and T-47D (Breast) 
               
It is clear from the IC50 values, that the compounds 3e, 3f, 4e, 4f, 7e and 7f show significant cytotoxic activity against both 
the cancer cell lines. It is evident from the data that even the position of substituent on the aromatic ring influences the 
relative toxicity which can be attributed to their differences in either the bioavailability or the protein binding properties. The 
above compounds are being further modified for attaining better analogs.  
Conclusion: Three series of novel non-estrogenic steroidal congeners were synthesized and screened for anticancer 
activity against human breast cancer cell lines. From the data it was found that most of the compounds are having 
promising anticancer activity and the compounds 3e, 3f, 4e and 4f were found to be the most active against both the cell 
lines.  
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3a
3b
3c
3d
3e
3f
3g
3h
3i
3j
4.33 3.31 4a 11.00.43
1.44 1.53 4b
1.50
1.421.60 2.79
2.53 1.86 4c
4.18
1.671.84
3.86
3.35 4.11 4d
ND
8.114.84 4.63
1.340.62 4e 0.620.640.79 13.0
2.350.31 4f 0.670.561.60 2.67
1.08 20.4 4g 10.048.1ND 10.6
2.27 3.35 4h
2.810.71.91 3.44
12.7 11.8 4i 12.9
29.223.1 9.05
2.34 2.45 4j 5.1032.2
17.5 20.2
Entry
1.26
MCF-7 T-47D Entry EntryMCF-7 T-47D T-47DMCF-7
7a
7b
7c
7d
7e
7f
7g
7h
7i
7j
2.69
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